Recardio Completes Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin

SAN FRANCISCO: SAN FRANCISCO, May 19, 2021 /PRNewswire/ -- The clinical study was designed to evaluate the safety and efficacy of Recardio's lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with stent placement. The...

Click to view original post